Deciphering the lactylation landscape in glioma: a novel gene signature predicts patient survival and immunotherapy sensitivity
We defined a novel LRGs signature integrating metabolic and immune dysregulation in glioma. This signature served as an independent predictor of prognosis and immunotherapy. Furthermore, we identified HSPE1 as a critical driver of glioma progression.
Authors
- Honglan Zhang
- Xiaolong Tang (ORCID: https://orcid.org/0000-0003-2201-5812)
- Gongming Zhang (ORCID: https://orcid.org/0000-0001-7354-2503)
- Sujie Jiang
- Xuzhu Gao
- Qiao Wang (ORCID: https://orcid.org/0000-0003-3927-8870)
- Yi Liu (ORCID: https://orcid.org/0000-0003-0240-0369)
- Yanbin Dong (ORCID: https://orcid.org/0000-0001-5561-1683)
- Congying Yang
Institutions
- Xuzhou Medical College (CN)
- Lianyungang Oriental Hospital (CN)
- Shandong Tumor Hospital (CN)
- The First People’s Hospital of Lianyungang (CN)
- Shandong First Medical University (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1664347
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00